A historic and scientific review of breast cancer: The next global healthcare challenge

Becker, Sven

doi:10.1016/j.ijgo.2015.03.015

Cited by 104 publications

(64 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although widely studied, breast cancer still currently represents the deadliest cancer for women worldwide. 1 Among breast cancer subtypes, the Her2+ ones were once associated with dismal prognostics until the approval in the early 2000's of trastuzumab (Herceptin ® ), an anti-Her2 monoclonal antibody. 2,3 Combined with taxanes (ie, docetaxel or paclitaxel) it has been approved as first-line treatment for Her2+ patients.…”

Section: Introductionmentioning

confidence: 99%

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer

Rodallec¹,

Sicard²,

Giacometti³

et al. 2018

IJN

View full text Add to dashboard Cite

PurposeNanoparticles are of rising interest in cancer research, but in vitro canonical cell monolayer models are not suitable to evaluate their efficacy when prototyping candidates. Here, we developed three-dimensional (3D) spheroid models to test the efficacy of trastuzumab-docetaxel immunoliposomes in breast cancer prior to further testing them in vivo.Materials and methodsImmunoliposomes were synthesized using the standard thin film method and maleimide linker. Two human breast cancer cell lines varying in Her2 expression were tested: Her2+ cells derived from metastatic site: mammary breast MDA-MB-453 and triple-negative MDA-MB-231 cells. 3D spheroids were developed and tested with fluorescence detection to evaluate viability. In vivo efficacy and biodistribution studies were performed on xenograft bearing nude mice using fluorescent and bioluminescent imaging.ResultsIn vitro, antiproliferative efficacy was dependent upon cell type, size of the spheroids, and treatment scheduling, resulting in subsequent changes between tested conditions and in vivo results. Immunoliposomes performed better than free docetaxel + free trastuzumab and ado-trastuzumab emtansine (T-DM1). On MDA-MB-453 and MDA-MB-231 cell growth was reduced by 76% and 25%, when compared to free docetaxel + free trastuzumab and by 85% and 70% when compared to T-DM1, respectively. In vivo studies showed tumor accumulation ranging from 3% up to 15% of the total administered dose in MDA-MB-453 and MDA-MB-231 bearing mice. When compared to free docetaxel + free trastuzumab, tumor growth was reduced by 89% (MDA-MB-453) and 25% (MDA-MB-231) and reduced by 66% (MDA-MB-453) and 29% (MDA-MB-231) when compared to T-DM1, an observation in line with data collected from 3D spheroids experiments.ConclusionWe demonstrated the predictivity of 3D in vitro models when developing and testing nanoparticles in experimental oncology. In vitro and in vivo data showed efficient drug delivery with higher efficacy and prolonged survival with immunoliposomes when compared to current anti-Her2 breast cancer strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer

Rodallec¹,

Sicard²,

Giacometti³

et al. 2018

IJN

View full text Add to dashboard Cite

show abstract

“…Breast cancer accounts for 30% of the newly diagnosed cases of cancer in women [1][2][3], with most cancer-related deaths occurring as a result of metastasis to distal organs [4]. Breast cancer metastasis is a sequential process driven by several factors and it begins with local invasion in the host tissue [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells

et al. 2020

View full text Add to dashboard Cite

Introduction: Metastatic breast cancer has poor prognosis due to limited therapeutic options. Protein kinase dysregulations have a major role in breast cancer progression and metastasis. In this study, we investigated the anti-cancer activity of sorafenib, a multikinase inhibitor, which targets receptor tyrosine kinases in breast cancer. Although treatment with sorafenib has increased the patient survival and inhibited metastatic migration in hepatocellular carcinoma, its role in breast cancer migration, metastasis, and intracellular signaling modulation is unknown. Methods: Breast cancer cell lines MCF7 and MDA-MB-231 were treated with sorafenib and its effect on proliferation, migration, invasion and gene expression was analyzed. Results: We found that sorafenib has an anti-proliferative and cytotoxic effect on breast cancer cells. Importantly, sorafenib inhibited the migration and invasion of breast cancer cells in vitro. Mechanistically, sorafenib increased mitochondrial superoxide production, suppressed breast cancer stem cell self-renewal, inhibited epithelial mesenchymal transition and ERK signaling. Con-clusion: Thus, sorafenib has anti-cancer activity against breast cancer cells and could improve the survival of breast cancer patients by inhibiting their invasive and metastatic properties.wells in DMEM with 2% FBS and spheroids were allowed to migrate. Invasion of the cells from the spheroid into the collagen matrix was monitored and documented microscopically. Colony Formation AssayOne hundred cells were plated in each well of a 6-well plate and treated with test materials for 48 h. Fresh media was added

show abstract

“…The markers and clinical parameters known to date (tumor size, expression of estrogen and progesterone receptors, and HER-2/neu, histological or nuclear grade) are not applicable in all clinical stages and between the patients, and limit their utility to decide the most appropriate chemotherapeutic treatment since they have shown a weak association with the clinical response of patients [4]. The involvement of axillary lymph nodes has been shown to be the most important predictor of disease-free survival and overall survival in breast cancer [5,6]. Approximately Ivyspring International Publisher 30% of lymph node-negative patients have a relapse within 10 years, compared with around 70% of patients with axillary nodal positive involvement [7,8].…”

Section: Introductionmentioning

confidence: 99%

Differential impact of classical and non-canonical NF-κB pathway-related gene expression on the survival of breast cancer patients

Espinoza-Sánchez

Kiesel

Fuentes-Pananá

et al. 2019

Senologie - Zeitschrift Für Mammadiagnostik Und -Therapie

View full text Add to dashboard Cite

Inflammation is a well-known driver of carcinogenesis and cancer progression, often attributed to the tumor microenvironment. However, tumor cells themselves are capable of secreting a variety of inflammatory molecules, leading to the activation of specific signaling pathways that promote tumor progression. The NF-κB signaling pathway is one of the most important connections between inflammation and tumorigenesis. NF-κB is a superfamily of transcription factors that plays an important role in several types of hematological and solid tumors, including breast cancer. However, the role of the NF-κB pathway in the survival of breast cancer patients is poorly studied. In this study, we analyzed and related the expression of both canonical and alternative NF-κB pathways and selected target genes with the relapse-free and overall survival of breast cancer patients. We used the public database Kaplan-Meier plotter (KMplot) which includes gene expression data and survival information of 3951 breast cancer patients. We found that the expression of IKKα was associated with poor relapse-free survival in patients with ER-positive tumors. Moreover, the expression of IL-8 and MMP-1 was associated with poor relapse-free and overall survival. In contrast, expression of IKKβ, p50, and p65 from the canonical pathway, and NIK and RELB from the alternative pathway correlated with better relapse-free survival also when the patients were classified by their hormonal and nodal status. Our study suggests that the expression of genes of the canonical and alternative NF-κB pathways is ultimately critical for tumor persistence. Understanding the communication between both pathways would help to find better therapeutic and prophylactic targets to prevent breast cancer progression and relapse.

show abstract

A historic and scientific review of breast cancer: The next global healthcare challenge

Cited by 104 publications

References 22 publications

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer

Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells

Differential impact of classical and non-canonical NF-κB pathway-related gene expression on the survival of breast cancer patients

Contact Info

Product

Resources

About